NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

800.95 0.45 (0.06%)

25.98% Gain from 52W Low

193.0K NSE+BSE Volume

NSE 09 Oct, 2026 3:31 PM (IST)

15,743.7

Market Cap

High in industry

Beta 1Year

Low volatility

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Search Inside the pdf :

Alembic Pharmaceuticals Ltd.

05 Aug 2026

800.95

0.06%

Outlook

Hold: Alembic Pharmaceuticals Ltd.

Target

Deven Choksey

Alembic Pharmaceuticals is well positioned to sustain its growth momentum over the coming quarters, supported by strong traction in the U.S. generics business, a healthy pipeline of limited-competition launches, and the full-quarter contribution from bosutinib following its 180- day exclusivity.

Number of FII/FPI investors decreased from 188 to 179 in Jun 2026 qtr

Alembic Pharmaceuticals Ltd.

04 Aug 2026

800.95

0.06%

Outperformance in the US drives an earnings beat in 1Q

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered a better-than-expected financial performance with a 12%/19%/13% beat on revenue/EBITDA/PAT for 1QFY27. Strong growth in export formulations and the API segment resulted in a positive earnings surprise for the quarter.

Alembic Pharmaceutic.. has an average target of 913.50 from 4 brokers.

Alembic Pharmaceuticals Ltd.

19 May 2026

800.95

0.06%

US Generics Strength, Animal Health Outperformance, and Ex- US Expansion Drive Diversified Growth

Accumulate: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 10.7% / 20.4% / 20.2% for the period of FY26-FY28E. The company is currently trading at 15x FY28E and we value the company at a PE of 17x FY28E EPS, implying a target price of INR 840 with the upside of 14%.

Number of FII/FPI investors decreased from 188 to 179 in Jun 2026 qtr

Alembic Pharmaceuticals Ltd.

16 May 2026

800.95

0.06%

Alembic Pharma (BUY): Higher R&D spend underscores focus on US market

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA was reported 4%/24.5% below our estimates; PAT reported 11.9% above our estimates on reporting tax credit

Number of FII/FPI investors decreased from 188 to 179 in Jun 2026 qtr

Alembic Pharmaceuticals Ltd.

05 Feb 2026

800.95

0.06%

Ex-US and Animal Health perform, while DF and US lag

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) exhibited in-line revenue with a slight miss on EBITDA/PAT for the quarter. While ex-US export growth was strong for the quarter, it was offset by moderate YoY growth in domestic formulation (DF) and US sales.

Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 781.8

Alembic Pharmaceuticals Ltd.

05 Nov 2025

800.95

0.06%

Strong Q2FY26 performance driven by US generics, margin expansion, and broad-based growth momentum

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Alembic Pharma is expected to maintain steady growth momentum supported by its expanding complex generics portfolio in the US, sustained traction in Ex-US markets, and a gradual recovery in the domestic formulations business.

Alembic Pharmaceuticals Ltd. is trading below its 30 day SMA of 827.8

Alembic Pharmaceuticals Ltd.

05 Nov 2025

800.95

0.06%

Export drives the show; India outlook cloudy

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q2FY26 result beat our expectations – led by formulations exports (up 25.1% YoY) while India continued to grow at a modest pace (4.9% in Q2FY26).

Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 781.8

Alembic Pharmaceuticals Ltd.

05 Nov 2025

800.95

0.06%

Alembic Pharma (BUY): All-round beat, US branded product entry to drive margins

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported 7%/4%/8% above our estimates. EBITDA margin was marginally 50 bps below our estimates

Alembic Pharmaceuticals Ltd. is trading below its 30 day SMA of 827.8

Alembic Pharmaceuticals Ltd.

05 Nov 2025

800.95

0.06%

Strong Q2FY26 performance driven by US generics, margin expansion, and broad-based growth momentum

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 781.8

Alembic Pharmaceuticals Ltd.

12 Aug 2025

800.95

0.06%

Steady Q1FY26 performance with positive FY26E outlook

Accumulate: Alembic Pharmaceuticals Ltd.

Deven Choksey

We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.

Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 781.8

Is Alembic Pharmaceuticals Ltd. worth buying?

246 Votes:

Buy 84.15%

Sell 8.13%

Hold 7.72%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf